CEL-SCI Announces Proposed Public Offering of Common Stock and Warrants; Medtronic Rejected by High Court on Edwards Valve Patent Print
By Staff and Wire Reports   
Monday, 07 October 2013 19:22
Below is a look at some of the headlines for companies that made news in the healthcare sector on October 7, 2013.

, a late-stage oncology company, today announced that it intends to offer and sell common stock and warrants, subject to market and other conditions, in an underwritten public offering.

The shares and warrants are being offered under the Companys effective shelf registration statement previously filed with the Securities and Exchange Commission (SEC). CEL-SCI intends to use the net proceeds of the offering for general corporate purposes, including working capital and operational purposes, and including product development.

Chardan Capital Markets is acting as sole bookrunner for the offering and Laidlaw & Company (UK) Ltd. is acting as co-manager on the deal.

The securities will be offered by means of a prospectus supplement and accompanying prospectus, forming a part of the effective registration statement, a copy of which may be obtained, when available, at the website of the SEC (SCUR) at http://www.sec.gov. Electronic copies of the preliminary prospectus also may be obtained from Chardan Capital Markets, LLC Capital Markets, 17 State Street, Suite 1600, New York, NY 10004, at 646-465-9012.


The U.S. Supreme Court left intact a patent ruling that may cost a Medtronic Inc. (NYSE:MDT) unit more than $200 million in its clash with Edwards Lifesciences Corp. (NYSE:EW) over devices that repair aortic valves without open-heart surgery.

The justices today turned away an appeal from Medtronic’s CoreValve unit, which a jury concluded infringed an Edwards heart-valve patent. A lower court upheld the jury’s $74 million verdict in November.

Medtronic last year paid Edwards $84 million and recorded a $245 million charge to cover estimated damages. The Minneapolis-based company also faces the prospect of a court order barring U.S. manufacture or sale of its infringing devices.

Edwards sued CoreValve, then a stand-alone company, in 2008. The patent was issued in 1995, and Edwards said it’s seeking an extension of the life of the patent to 2017.

The devices use catheters to thread replacement valves into the body. The U.S. market could reach $2.5 billion, Jason Mills, an analyst with Canaccord Adams Inc. in San Francisco, said last year.

At the Supreme Court, Medtronic argued that the disputed patent didn’t contain enough information to enable reproduction of the invention, as required under federal law.

Also Monday:

Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE)
today announced interim results from the ongoing 450 patient, dose finding, 505 (b) 2 study of OptinaTM as a treatment for Diabetic Macular Edema (DME).

Arch Therapeutics, Inc. (OTCQB: ARTH)
, a life sciences company and developer of AC5™, a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, is pleased to announce that the Massachusetts Life Sciences Center, a quasi-public agency tasked with implementing the state's $1 billion Life Sciences Initiative, has concluded the requisite steps to award Arch with a $1 million dollar Accelerator Loan.

Athersys, Inc. (Nasdaq:ATHX)
announced today that Gil Van Bokkelen, Chairman and CEO of Athersys, will present at the 3rd Annual Regenerative Medicine (Regen Med) Partnering Forum, part of the Stem Cell Meeting on the Mesa to be held October 14-16 in La Jolla, CA.

Beamz Interactive, Inc. (OTCQB: BZIC)
, an emerging growth technology company specializing in state-of-the-art interactive music products, today announced shipment of its new education and healthcare offering.

, a biopharmaceutical development company, announced today that a Notice of Allowance has been issued by the United States Patent and Trademark Office (USPTO) for a patent application claiming the composition of BL-5010, a novel composition for the non-surgical removal of skin lesions.

BioSpecifics Technologies Corp. (NASDAQ: BSTC)
, a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S. and XIAPEX® in the EU, announced today that data from multiple trials evaluating the use of XIAFLEX in adult patients with Dupuytren's contracture with a palpable cord were presented by BioSpecifics' partner Auxilium Pharmaceuticals, Inc. at the 68th Annual Meeting of the American Society for Surgery of the Hand that took place in San Francisco, California, on October 3 – 5, 2013.

Cardium Therapeutics (NYSE MKT: CXM)
today provided an update on its exchange listing.  As previously reported, a communication from the staff of the Company's current listing exchange, NYSE MKT, indicated that the Company was considered to be noncompliant with certain listing requirements based on its quarterly report for the period ended September 30, 2012, and provided that the company should submit a plan to staff of the exchange that would reestablish compliance with the NYSE MKT listing requirement by March 31, 2013.

Fuse Science, Inc. (OTCQB: DROP)
, a consumer products and delivery technology company that is developing new, patent-pending technologies poised to redefine how consumers receive energy, medicines, vitamins and minerals announced today that as of late last month it has officially launched the first wave of what is believed to be the next generation of commercial advertising.

GeoVax Labs, Inc. (OTCQB: GOVX)
, a biotechnology company developing preventive and therapeutic HIV vaccines, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application U.S. 10/336,566 entitled, "Compositions and Methods for Generating an Immune Response."

Green Endeavors, Inc. (OTCQB: GRNE)
, a majority owned subsidiary of Nexia Holdings, Inc. (PINKSHEETS: NXHD), announced continued revenue growth in the month of September 2013 over the comparable month in 2012.

iBio, Inc. (NYSE MKT: IBIO)
, a biotechnology company focused on commercializing its proprietary transformative recombinant platform technology for development and production of biologics using transient gene expression in unmodified green plants, today confirmed, as required by Section 610(b) of the NYSE MKT Company Guide, the receipt of an audit opinion for its year ended June 30, 2013, containing a going concern qualification.  

IDS Industries, Inc. (OTCBB: IDST)
provided today the information necessary to participate in its upcoming Investor Conference Call scheduled for October 14, 2013 at 4:30pm EDT, just after market close. CEO Scott Plantinga will provide shareholders and interested investors an update on the corporate efforts to date regarding its portable generators and energy storage systems along with a general discussion of the Company's other business activities.

IntelliCell Biosciences, Inc. (OTCQB: SVFC)
, a regenerative medicine company utilizing adult autologous vascular cells (SVC's) derived from the blood vessels, announced today that it has filed its 10Q quarterly report and is now in full compliance with SEC regulations as a fully reporting public company as reflected under the Securities Exchange Act of 1934.

IntraOp Medical Corporation, a leading provider of innovative technology-based cancer treatments, today announced the completion of its sale to an investment group led by Firsthand Technology Value Fund. Inc. (NASDAQ: SVVC), a publicly traded venture capital fund.

KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH)
today announced it has commenced an underwritten public offering of shares of its common stock to raise aggregate proceeds of $100 million.

Merit Medical Systems, Inc. (Nasdaq:MMSI)
, a leading manufacturer and marketer of proprietary disposable medical devices used in interventional and diagnostic procedures, particularly in cardiology, radiology and endoscopy, announced today that the Company will release its financial results for the third quarter ended September 30, 2013, after the close of the stock market on Wednesday, October 23rd, 2013.

MiMedx Group, Inc.  (NASDAQ: MDXG)
, an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it will present at the 32nd Annual J. P. Morgan Healthcare Conference.  

MWI Veterinary Supply, Inc. (NASDAQ: MWIV)
announced today that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act for the proposed acquisition of substantially all of the assets of IVESCO Holdings LLC expired on October 3, 2013.

Neurotrope, Inc. (formerly BlueFlash Communications, Inc.) (OTCQB: NTRP), a Nevada corporation, announced today that it has formally hired Robert Weinstein to be its Executive Vice President and Chief Financial Officer.

Novavax, Inc. (Nasdaq:NVAX)
today announced that enrollment has begun in a Phase 2 dose-confirmatory clinical trial of its respiratory syncytial virus (RSV) vaccine candidate in women of childbearing age.

NuVasive, Inc. (NASDAQ: NUVA)
, a medical device company focused on developing minimally disruptive surgical products and procedures for the spine, announced today that it will exhibit several game-changing new products and procedurally integrated solutions at the 28th Annual North American Spine Society (NASS) Annual Meeting, which will be held October 9-12, 2013, at the Ernest N. Morial Convention Center in New Orleans, La.

Oncothyreon Inc. (NASDAQ: ONTY)
today announced the presentation of final results from the first Phase 1 trial of ONT-380 at the American Association for Cancer Research Special Conference on Advances in Breast Cancer Research in San Diego.

Quidel Corporation (NASDAQ: QDEL)
, a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, will release third quarter 2013 financial results after market close on Wednesday, October 23, 2013.

Sangamo BioSciences, Inc. (Nasdaq: SGMO)
announced today that Elizabeth Wolffe, Ph.D., Sangamo's senior director of corporate communications, will give a company presentation at the 3rd Annual Regen Med Partnering Forum, part of the Stem Cell Meeting on the Mesa to be held October 14-16, 2013, in La Jolla, CA.

TelVue® Corporation (PINKSHEETS: TEVE)
, the innovation leader in Television and Internet Broadcasting for communities, cable operators, and media companies is pleased to provide the Vermont Access Network (VAN) with the powerful cloud-based TelVue® Connect™ platform for the exchange of broadcast-quality programming among VAN member stations.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus